Certainly this is good news for the cancer drug market. AstraZeneca announced recently that its immunotherapy drug Imfinzi has been granted a new status by U.S. regulators. It will now be considered as a “breakthrough” designation by U.S. regulators for treating non-metastic lung cancer.
This status allows the drug to, hopefully, have a quick regulatory review and it confirms that the drug is working for early stage lung cancer.
Learn more about the drug and its new status.